Conjunctivitis in dupilumab clinical trials.

ABSTRACT:

Background

Dupilumab blocks the shared receptor component for interleukin (IL)-4 and IL-13. It is approved in the U.S.A. for patients aged ≥ 12 years with moderate-to-severe atopic dermatitis (AD) uncontrolled by topical prescription medicines or who cannot use topical medicines, for patients in Japan whose AD is uncontrolled with existing therapies, for patients with moderate-to-severe AD in Europe who are candidates for systemic therapy and for patients aged ≥ 12 years for maintenance treatment of moderate-to-severe asthma uncontrolled with their current medicines. AD trials have reported increased incidence of conjunctivitis for dupilumab vs. placebo.

Objectives

To characterize further the occurrence and risk factors of conjunctivitis in dupilumab clinical trials.

Meth

SUBMITTER: Akinlade B 

PROVIDER: S-EPMC6850316 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature